Role of 150 mg bicalutamide in the treatment of prostate cancer: 3rd analysis of the EPC (early prostate cancer) program
Fourcade, R-Olivier.; Richaud, P.; Coloby, P.; Malavaud, B.
Progres en Urologie Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 17(4 Suppl. 1): 891-910
2007
ISSN/ISBN: 1166-7087 PMID: 17650746 Document Number: 610661
Document emailed within 1 workday
Related Documents
Stav, S.Y.; Segal, G. 2002: The role of bicalutamide in the treatment of prostate cancer Harefuah 141(4): 379-383; 408, 407Shioi, K.; Sakai, N.; Yoshida, M.; Nakamura, M. 2005: Successful recovery from interstitial pneumonitis, induced by bicalutamide and leuprorelin acetate given as treatment for prostate cancer Hinyokika Kiyo. Acta Urologica Japonica 51(3): 211-214
Topuzov, M.E. 2007: Role of density of prostate-specific antigen transitory zone in early diagnosis of prostate cancer Voprosy Onkologii 53(3): 295-297
De la Taille, A.; Houlgatte, A.; Houdelette, P.; Berlizot, P.; Ramirez, J.; Ricordel, I. 1997: Value of free/total prostate specific antigen in the early diagnosis of prostate cancer (study of 105 patients) Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 7(2): 240-245
Galić, J.; Karner, I.; Cenan, L.; Tucak, A.; Hegedus, I.; Pasini, J.; Bilandzija-Peranović, M.; Mihaljević, S. 2003: Comparison of digital rectal examination and prostate specific antigen in early detection of prostate cancer Collegium Antropologicum 27(Suppl 1): 61-66
Bostwick, D.G. 1994: Prostate-specific antigen. Current role in diagnostic pathology of prostate cancer American Journal of Clinical Pathology 102(4 Suppl 1): S31-S37
Hardeman, S.W.; Wake, R.W.; Soloway, M.S. 1989: Two new techniques for evaluating prostate cancer. The role of prostate-specific antigen and transrectal ultrasound Postgraduate Medicine 86(2): 197-8 201 204 Passim
Erdamar, S.; Yang, G.; Harper, J.W.; Lu, X.; Kattan, M.W.; Thompson, T.C.; Wheeler, T.M. 1999: Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology Inc 12(8): 751-755
Murray, N.P.; Aedo, S.óc.; Reyes, E.; Fuentealba, C.; Jacob, O. 2019: Primary circulating prostate cells, age and prostatic volumen predict the presence of prostate cancer in men with indication of a second prostate biopsy Archivos Espanoles de Urologia 72(1): 16-24
Romppanen, J.; Haapalainen, T.; Punnonen, K.; Penttilä, I. 2002: Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer Anticancer Research 22(1a): 415-420
Perrin, P.; Mouriquand, P.; Monsallier, M.; Oukeira, H.; Maquet, J.H.; Devonec, M. 1989: Early diagnosis of cancer of the prostate. Hypothetic role of transrectal echography Presse Medicale 18(26): 1289-1292
Sun, S.-C.; Zhao, H.; Liu, R.; Wang, B.-L.; Liu, Y.-Q.; Zhao, Y.; Shi, Z.-D. 2017: Expression of long non-coding RNA H19 in prostate cancer and its effect on the proliferation and glycometabolism of human prostate cancer cells Zhonghua Nan Ke Xue 23(2): 120-124
Horiguchi, A.; Hatakeyama, N.; Ikeuchi, K. 1999: Dynamics of prostate-specific antigen as prognostic factors in endocrine treatment for prostate cancer Hinyokika Kiyo. Acta Urologica Japonica 45(1): 31-35
Grosclaude, P.; Menegoz, F.; Schaffer, P.; Macé Lesec'h, J.; Arveux, P.; Le Mab, G.; Soulié, M.; Villers, A. 1997: Prostate cancer screening (II): is prostate cancer a public health problem? Update of incidence and mortality figures in France from 1982 to 1990 Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 7(4): 647-654
Considine, B.; Petrylak, D.P. 2019: Integrating Novel Targets and Precision Medicine into Prostate Cancer Care-Part 1: the Non-Androgen-Targetable Pathways in Castration-Resistant Prostate Cancer Oncology 33(3): 113-118
Habib, F.K.; Ross, M.; Bayne, C.W. 1999: Factors controlling the expression of 5alpha-reductase in human prostate: A possible new approach for the treatment of prostate cancer European Urology 35(5-6): 439-442
Liu, J-he.; Li, H-wei.; Tong, M.; Li, M.; Na, Y-qun. 2004: Genetic risk factors of prostate cancer in Han nationality population in Northern China and a preliminary study of the reason of racial difference in prevalence of prostate cancer Zhonghua Yi Xue Za Zhi 84(5): 364-368
Ragde, H.; Grado, G.L.; Nadir, B.S. 2001: Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone Archivos Espanoles de Urologia 54(7): 739-747
Perrin, P.; François, O.; Maquet, J.H.; Bringeon, G.; Duteil, P.; Devonec, M. 1991: Circulating prostate cancer specific antigens in benign hypertrophy and localized cancer of the prostate Presse Medicale 20(28): 1313-1319
Wu, C.T.; Chuang, C.K.; Chou, C.C.; Chu, S.H.; Chen, H.W.; Chen, C.S.; Chiang, Y.J.; Liao, S.K. 2000: The role of free to total prostate-specific antigen ratio for prostate cancer in screening patients with total serum levels between 4 and 20 ng/ml Chang Gung Medical Journal 23(3): 142-148